Simvastatin Augmentation of Lithium Treatment in Bipolar Depression
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Bipolar Disorder
In brief
Primary Aim: To estimate the antidepressant efficacy of simvastatin versus placebo as an adjunct to lithium, valproate, and/or other atypical antipsychotic therapy among individuals with bipolar I disorder in a nonpsychotic major depressive episode. Hypothesis: Simvastatin will be superior to placebo in improvement of depressive symptoms assessed by the Montgomery-Asberg Depression Rating Scale (MADRS).
Key facts
- Study ID
- NCT01665950
- Run by
- Massachusetts General Hospital
- People needed
- 4
- Starts
- 2012-08-01
- Expected to finish
- 2014-10-01
- Last updated by the study team
- 2017-05-09
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.